MHRA probes UK peptide clinics for illegal claims
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- MHRA is investigating UK peptide clinics for making illegal medicinal claims about unregulated experimental peptides.
- MHRA says clinics making medicinal claims will be considered medicines under Human Medicines Regulations 2012 and will face enforcement action.
- Clinic advertised Cortexin for neuroprotection, BPC‑157 for tissue repair, and Thymosin Alpha for immune function, claims the MHRA deemed illegal medicinal claims; the clinic removed the claims after being contacted.
- Clinic offers seven peptides labeled “research only” with prices of £350 per month for a single peptide and £450 for two, providing them in vials with disposable syringes or pre‑loaded injection pens for an extra fee.
- Clinician recommended BPC‑157 and MOTS‑C for recovery after exercise, describing BPC‑157 as aiding cell repair and warning against use by smokers or those with a family history of cancer.
- Lynda Scammell explained that the MHRA assesses each product case‑by‑case and will disregard “research only” claims used to evade medicines regulations.
- UK consumers are obtaining peptide products through unregulated online channels and messaging platforms, lacking clinical oversight, quality assurance, or safety screening.
Why it matters: Patients seeking quick anti‑ageing or recovery fixes lose a risky shortcut as the MHRA moves to enforce the Human Medicines Regulations, while clinics risk fines or closure for illegal medicinal claims; the regulator’s action also signals tighter oversight of a booming, largely unproven peptide market.
